

**Supplementary Table 1: Characteristics and relationship of clinical features to FGFR expression (n=47).**

Variable	n	FGFR3			FGFR4		
		Median	(Range)	P*	Median	(Range)	P*
<b>TOTAL</b>	47	110.70	(35.66-211.83)		11.07	(1.22-67.76)	
<b>Age at diagnosis</b>				0.76			0.61
> 35 years	20	108.86	(35.66-211.83)		8.66	(1.22-67.76)	
≤ 35 years	27	110.78	(43.49-163.82)		12.72	(1.95-54.88)	
<b>Sex</b>				0.90			0.48
Male	20	110.78	(35.66-211.83)		12.72	(1.22-67.76)	
Female	27	110.19	(41.27-167.50)		7.06	(1.95-54.88)	
<b>Body Mass Index</b>				0.41			0.96
Normal (< 25)	13	132.47	(69.56-185.80)		15.13	(3.06-67.76)	
Overweight (25-29.9)	19	110.78	(43.49-156.84)		12.72	(1.95-54.88)	
Obese (≥ 30)	4	101.22	(88.13-137.60)		9.83	(6.27-43.48)	
Unknown	11	103.53	(35.66-211.83)		8.42	(1.22-20.61)	
<b>Year of Diagnosis</b>				0.38			0.08
1980-1989	3	109.69	(69.56-133.88)		5.91	(3.06-7.88)	
1990-1999	18	85.87	(43.49-185.80)		10.78	(1.22-42.67)	
2000-2009	26	113.83	(35.66-211.83)		14.10	(4.00-67.76)	
<b>Site</b>				0.13			0.55
Trunk	7	133.88	(70.77-156.84)		15.45	(6.53-54.88)	
Upper Extremity	6	125.50	(88.13-211.83)		9.71	(4.00-17.38)	
Lower Extremity	34	102.55	(35.66-185.80)		10.78	(1.22-67.76)	
<b>Tumor size, 5 cm cut pt</b>				0.75			0.37
≤ 5 cm	14	106.44	(35.66-211.83)		9.20	(1.22-33.28)	
> 5 cm	31	110.78	(43.49-185.80)		12.72	(1.95-67.76)	
Unknown	2	94.38	(41.27-147.49)		18.03	(15.45-20.61)	
<b>Tumor size, 7 cm cut pt</b>				0.84			0.64
≤ 7 cm	23	110.70	(35.66-211.83)		9.98	(1.22-53.29)	
> 7 cm	22	109.40	(43.49-185.80)		13.07	(1.95-67.76)	
Unknown	2	94.38	(41.27-147.49)		18.03	(15.45-20.61)	
<b>Histologic Subtype</b>				0.22			0.33
Monophasic	27	110.78	(43.49-221.83)		11.07	(1.22-67.76)	
Biphasic	20	105.63	(35.66-185.80)		11.49	(3.06-54.88)	
<b>Pre-treated w/Chemotherapy or Radiation</b>				0.84			0.32
Yes	13	109.69	(48.54-185.80)		7.88	(1.22-54.88)	
No	34	110.74	(35.66-211.83)		12.89	(1.95-67.76)	
<b>Radiation</b>				0.88			0.70
Yes	30	110.98	(35.66-182.41)		9.44	(1.22-54.88)	
No	15	110.70	(41.27-211.83)		13.07	(3.06-67.76)	
Unknown	2	104.31	(67.70-140.91)		15.94	(15.13-16.74)	
<b>Chemotherapy</b>				0.18			0.16
Yes	24	123.02	(48.54-211.83)		14.07	(1.22-67.76)	
No	23	109.36	(35.66-175.95)		9.98	(1.95-42.67)	
<b>Metastatic disease at diagnosis</b>				0.37			0.88
Yes	3	135.68	(77.85-185.80)		11.07	(6.53-30.73)	
No	44	110.19	(35.66-211.83)		11.49	(1.22-67.76)	

\*Wilcoxon or Kruskal-Wallis tests as necessary

**Supplementary Figure 1: Progression-Free Survival for SS Patients Diagnosed from 1980-2010. [A]** by gender and **[B]** by BMI at or near time of diagnosis: normal versus overweight/obese, excluding unknown and patients less than 18 years of age (n=80).

